Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 19/20 | 0.85 |
| ▸ | INSR | P06213 | 15/20 | 0.85 |
| ▸ | IGF1R | P08069 | 15/20 | 0.85 |
| ▸ | AURKA | O14965 | 2/20 | 0.82 |
| ▸ | ROS1 | P08922 | 2/20 | 0.82 |
| ▸ | EML4 | Q9HC35 | 2/20 | 0.82 |
| ▸ | EGFR | P00533 | 3/20 | 0.79 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.79 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.79 |
| ▸ | JAK2 | O60674 | 1/20 | 0.79 |
| ▸ | STK10 | O94804 | 1/20 | 0.79 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.79 |
| ▸ | SLC34A2 | O95436 | 1/20 | 0.79 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.79 |
| ▸ | ABL1 | P00519 | 1/20 | 0.79 |
| ▸ | CD74 | P04233 | 1/20 | 0.79 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.79 |
| ▸ | LCK | P06239 | 1/20 | 0.79 |
| ▸ | FYN | P06241 | 1/20 | 0.79 |
| ▸ | FES | P07332 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29618196 | 1.00 | ALK (0.85) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916574 | 0.94 | ALK (0.86) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL21135587 | 0.93 | ALK (0.86) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916602 | 0.92 | ALK (0.85) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916477 | 0.92 | ALK (1.00) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL15498495 | 0.91 | ALK (0.84) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL22493313 | 0.91 | ALK (0.84) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL30090750 | 0.91 | ALK (0.84) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL11916595 | 0.91 | ALK (0.86) | ALKINSRIGF1RAURKAROS1 | |
| SCHEMBL22793620 | 0.90 | ALK (0.82) | ALKINSRIGF1RAURKAROS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3725771-B1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | UNIV SHANGHAI TECHNOLOGY (CN) | 2026-02-04 | — | — | EP | disclosed |
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2025-02-27 | — | — | US | disclosed |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | SHANGHAITECH UNIVERSITY (CN) | 2025-02-18 | — | — | US | disclosed |
| EP-4446324-A1 | LIGAND COMPOUNDS FOR E3 UBIQUITIN LIGASE, PROTEIN DEGRADERS DEVELOPED ON BASIS OF LIGAND COMPOUNDS, AND USES THEREOF | Gluetacs Therapeutics (Shanghai) Co., Ltd. (CN) | 2024-10-16 | — | — | EP | disclosed |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | SHANGHAITECH UNIVERSITY (CN) | 2023-10-03 | — | — | US | disclosed |
| CN-116239566-A | E3 ubiquitin ligase ligand compound, protein degradation agent developed based on ligand compound and application thereof | 标新生物医药科技(上海)有限公司 | 2023-06-09 | — | — | CN | disclosed |
| EP-4019021-A1 | COMPOUND INHIBITING AND INDUCING DEGRADATION OF EGFR AND ALK | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2022-06-29 | — | — | EP | disclosed |
| US-20220117982-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | SHANGHAITECH UNIVERSITY (CN) | 2022-04-21 | — | — | US | disclosed |
| CN-110357889-B | Protein degradation targeting compound, anti-tumor application thereof, intermediate thereof and application of intermediate | 上海科技大学 | 2022-03-15 | — | — | CN | disclosed |
| CN-109912655-B | ALK protein degradation agent and anti-tumor application thereof | 上海科技大学 | 2021-12-10 | — | — | CN | disclosed |
| WO-2020249048-A1 | ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF | 上海科技大学 | 2020-12-17 | — | — | WO | disclosed |
| WO-2020249048-A1 | ALK PROTEIN REGULATOR AND ANTI-TUMOR APPLICATION THEREOF | 上海科技大学 | 2020-12-17 | — | — | WO | disclosed |
| CN-112079866-A | ALK protein regulator and anti-tumor application thereof | 上海科技大学 | 2020-12-15 | — | — | CN | disclosed |
| EP-3725771-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | Shanghaitech University (CN) | 2020-10-21 | — | — | EP | disclosed |
| EP-3725771-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | Shanghaitech University (CN) | 2020-10-21 | — | — | EP | disclosed |
| US-20200306273-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2020-10-01 | — | — | US | disclosed |
| US-20200306273-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | SHANGHAITECH UNIVERSITY (CN) | 2020-10-01 | — | — | US | disclosed |
| WO-2019114770-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | 上海科技大学 | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200306273-A1 | ALK PROTEIN DEGRADATION AGENT AND ANTI-TUMOR APPLICATION THEREOF | ADRM1, VHL, MDM2 | ALK 5/4885INSR 1929/4885IGF1R 306/4885 |
| US-20250064837-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | ALK 2330/4885INSR 3244/4885IGF1R 1661/4885 |
| US-12226424-B2 | Target protein degradation compounds, their anti-tumor use, their intermediates and use of intermediates | UFM1, SUMO1, SUMO2 | ALK 2497/4885INSR 3225/4885IGF1R 1585/4885 |
| US-11771709-B2 | ALK protein degradation agent and anti-tumor application thereof | ADRM1, VHL, MDM2 | ALK 5/4885INSR 1929/4885IGF1R 306/4885 |
| US-20220117982-A1 | TARGET PROTEIN DEGRADATION COMPOUNDS, THEIR ANTI-TUMOR USE, THEIR INTERMEDIATES AND USE OF INTERMEDIATES | UFM1, SUMO1, SUMO2 | ALK 2497/4885INSR 3225/4885IGF1R 1585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.